Despite the impact from foreign exchange rate volatility which led to declining average selling prices, improved cost controls and operational capabilities mitigated the decline in net profit to RM31.1 million.
Gross profit margin is maintaining at a healthy rate of 22%.
Let's say whole year eps of 5.68 cents(s). Current price at 98.5 cents , PE of 17.34 times I think is trading at full value .
Reply to clim : Yeah, the initial question from sporeshare is which counter has good earnings power
theintelligentinvestor
Reply : Don't take this as detailed analysis, just my 2c.
1) ROE > 20% for the past 5 years
2) CAGR 2013-17 - Revenue 23%, Earnings 22, Equity 18%. Healthcare glove expected to grow at 8-12% in the next 3 years.
3) Debt - CR 3, Debt/Eq 4%
4) Smallest among the 5 glove manufactures, but their EBIT is clearly superior, ie 2-4x of the other 4, Hartalega, Top Glove, Kossan & Supermax.
5) Lastly, as compared to the others in the list. Riverstone product has a bigger global market than the other that are more local or within regional.
2) CAGR 2013-17 - Revenue 23%, Earnings 22, Equity 18%. Healthcare glove expected to grow at 8-12% in the next 3 years.
3) Debt - CR 3, Debt/Eq 4%
4) Smallest among the 5 glove manufactures, but their EBIT is clearly superior, ie 2-4x of the other 4, Hartalega, Top Glove, Kossan & Supermax.
5) Lastly, as compared to the others in the list. Riverstone product has a bigger global market than the other that are more local or within regional.
No comments:
Post a Comment